Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle. 

Polifarmacia en adultos mayores ¿Qué medicación no podemos suspender?

Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should we discontinue when it means risking patient health? This study recently presented at JAMA at least clarifies what drug NEVER to discontinue. 

The study looked at a cohort of 29,047 patients older than 65 who were on statins, hypertensive medication, antidiabetics and antiplatelets between 2013 and 2015.

This study was particularly focused on patients discontinuing statins. These were matched using propensity score to be compared against patients who stayed on all medication (statins and the rest). 

Of the total population of nearly 30,000 patients, 20% discontinued statins and kept taking the rest of prescribed medication; the rest of the population kept taking all drugs and served as control group. 

Patients discontinuing statins had higher risk of hospitalization for cardiac failure (HR 1.24; CI 95%, 1.07-1.43), any adverse cardiovascular event (HR, 1.14; CI 95%, 1.03-1.26), all cause death (HR, 1.15; CI 95%, 1.02-1.30) and emergency hospitalization for any cause (HR, 1.12; CI 95%, 1.05-1.19). 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


Comorbidities rate resulted very similar in both groups, which makes it hard to believe doctors would discontinue statins because of patient frailty. 

Conclusion

Patients receiving polypharmacy who for whatever reason discontinue statins (while still taking the rest of prescribed drugs) present increased risk of fatal and non-fatal events. 

rea-2021-oi-210393-1622769937-85783

Original Title: Cardiovascular Outcomes and Mortality Associated With Discontinuing Statins in Older Patients Receiving Polypharmacy.

Reference: Federico Rea et al. JAMA Netw Open. 2021 Jun 1;4(6):e2113186. doi: 10.1001/jamanetworkopen.2021.13186.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...